What Is Danuglipron? Everything You Should Know Before Starting
Quick Answer
Quick answer: Danuglipron is a oral non-peptide glp-1 receptor agonist (development discontinued). Phase 2 trials showed weight loss of 8-13% at 32 weeks. Note that human clinical evidence is limited; details below.
Danuglipron at a glance:
- Drug class: Oral non-peptide GLP-1 receptor agonist (development discontinued)
- Manufacturer: Pfizer
- Route: oral tablet
- Typical frequency: twice daily (in trials)
- Half-life: approximately 4-7 hours (twice daily dosing was tested)
- Receptor target: GLP-1 receptor
Danuglipron has become one of the more talked-about names in the oral non-peptide glp-1 receptor agonist (development discontinued) space. The clinical reality is more nuanced than the headlines suggest, and most of what matters fits in a few sentences. Danuglipron was a small-molecule oral GLP-1 agonist similar in concept to orforglipron.
What is Danuglipron?
Danuglipron was a small-molecule oral GLP-1 agonist similar in concept to orforglipron.
Danuglipron is manufactured by Pfizer. Danuglipron is not currently approved by the FDA for general human use. Available evidence comes from early-phase clinical work. We do not endorse self-administration of unapproved compounds.
The drug class oral non-peptide glp-1 receptor agonist (development discontinued) works by acting at the GLP-1 receptor. Let's walk through what that means in practice.
How Danuglipron Works in the Body
Danuglipron was a small-molecule oral GLP-1 agonist similar in concept to orforglipron. The receptor target — GLP-1 receptor — drives the downstream effects users care about: phase 2 trials showed weight loss of 8-13% at 32 weeks.
The pharmacokinetics matter for daily use. Danuglipron has a half-life of approximately 4-7 hours (twice daily dosing was tested), which determines how often it is dosed. The standard route of administration is oral tablet, and the typical schedule is twice daily (in trials).
For more detail on the underlying biology, see our breakdown of how Danuglipron works.
Who Uses Danuglipron?
Danuglipron is most relevant for people whose situation maps to its approved indications: development discontinued in 2025 due to a hepatotoxicity signal.
People who should avoid Danuglipron include those with the following:
- allergy to the active ingredient or any excipient
- pregnancy or breastfeeding (per label)
- conditions specifically called out in the prescribing information
Common and Serious Side Effects
The most commonly reported side effects of Danuglipron include:
- nausea
- vomiting
- diarrhea (dose-limiting)
Serious risks — uncommon but worth knowing — include:
- hepatotoxicity (program-ending finding)
We have a more detailed breakdown in our Danuglipron side-effects guide.
Danuglipron vs Alternatives
With danuglipron's program discontinued, orforglipron is the leading oral GLP-1 in late-stage development. If you are weighing Danuglipron against another option, our comparison pages include Danuglipron Side Effects: 7 Things to Watch For (and How to Manage Them), Danuglipron Outcomes Decoded: Who Responds Best and Why, Danuglipron Cost Explained: Monthly, Yearly, and How to Save.
Sponsored — Affiliate Disclosure
Ready to Start Your GLP-1 Journey?
Bottom Line
Danuglipron fits into a broader landscape of oral non-peptide glp-1 receptor agonist (development discontinued) options. The right choice for any individual depends on insurance, side-effect tolerance, dosing preference, and prescriber familiarity — usually more than on the molecule itself. Evidence remains preliminary; we recommend caution and clinician oversight. If you are considering Danuglipron, talk to a licensed clinician first — particularly if you take other medications.
Frequently Asked Questions
Frequently Asked Questions
Related Reading
- Danuglipron Side Effects: 7 Things to Watch For (and How to Manage Them)
- Danuglipron Outcomes Decoded: Who Responds Best and Why
- Danuglipron Cost Explained: Monthly, Yearly, and How to Save
- Danuglipron for Weight Loss: The Complete 2026 Guide
- Is Retatrutide Right for You? An Evidence-Based Breakdown
- What Nobody Tells You About Retatrutide Side Effects
Sources
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514.
- Frias JP et al. Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg. Lancet 2021;397:1736.
- Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.
Related Articles
- →Danuglipron Side Effects: 7 Things to Watch For (and How to Manage Them)
- →Danuglipron Outcomes Decoded: Who Responds Best and Why
- →Danuglipron Cost Explained: Monthly, Yearly, and How to Save
- →Danuglipron for Weight Loss: The Complete 2026 Guide
- →Is Retatrutide Right for You? An Evidence-Based Breakdown
- →What Nobody Tells You About Retatrutide Side Effects